Original Paper

World Journal of Microbiology and Biotechnology

, 26:171

First online:

Prevalence of multidrug-resistant Staphylococcus aureus in diabetics clinical samples

  • S. RajuAffiliated withDepartment of Biotechnology, Gulbarga UniversityDepartment of Microbiology and Cell Biology, Indian Institute of Science Email author 
  • , Ajay Kumar OliAffiliated withDepartment of Biotechnology, Gulbarga University
  • , S. A. PatilAffiliated withDepartment of Neuromicrobiology, National Institute of Mental Health and Neuro Sciences
  • , R. Kelmani ChandrakanthAffiliated withDepartment of Biotechnology, Gulbarga University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Antibiotic resistance in 40 Staphylococcus aureus clinical isolates from 110 diabetic patients (36%) was evaluated. Of these, 32 (80%) of the isolates showed multidrug-resistance to more than eight antibiotics and 35% isolates were found to be methicillin resistant S. aureus (MRSA). All 40 S. aureus strains (100%) screened from diabetic clinical specimens were resistant to penicillin, 63% to ampicillin, 55% to streptomycin, 50% to tetracycline and 50% to gentamicin. Where as low resistance rate was observed to ciprofloxacin (20%) and rifampicin (8%). In contrast, all (100%) S. aureus strains recorded susceptibility to teicoplanin, which was followed by vancomycin (95%). Genotypical examination revealed that 80% of the aminoglycoside resistant S. aureus (ARSA) have aminoglycoside modifying enzyme (AME) coding genes; however, 20% of ARSA which showed non-AME mediated (adaptive) aminoglycoside resistance lacked these genes in their genome. In contrast all MRSA isolates possessed mecA, femA genetic determinants in their genome.


Methicillin resistant Staphylococcus aureus Aminoglycoside modifying enzymes mecA and femA